At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02595 GENFLEET-B
Market Closed 10-16 16:08:16
27.860
+0.680
+2.50%
High29.600Low27.700Vol6.06M
Open28.120D1 Closing27.180Amplitude6.99%
Mkt Cap10.67BTradable Cap9.78BTotal Shares383.00M
T/O174.13MT/O Rate1.73%Tradable Shares351.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
GENFLEET-B (02595) Surges Over 8% in Morning Session as Company Releases Multiple Clinical Results for KRAS G12D Inhibitor
Stock News  ·  10-16 10:02
GENFLEET-B (02595) Surges Over 8% in Morning Session as Company Releases Multiple Clinical Results for KRAS G12D Inhibitor
Movement Alert｜GENFLEET-B Intraday Rise 8.31% in Regular Trading, clinical progress on GFH375 VS-7375 supports sentiment
Market Focus  ·  10-16 09:35
Movement Alert｜GENFLEET-B Intraday Rise 8.31% in Regular Trading, clinical progress on GFH375 VS-7375 supports sentiment
GenFleet's Oral Cancer Drug Enters Phase III Testing in China; Shares Up 3%
MT Newswires Live  ·  10-15 12:15
GenFleet's Oral Cancer Drug Enters Phase III Testing in China; Shares Up 3%
HK-Listed GenFleet Jumps on Positive Progress of Cancer Drug
Reuters  ·  10-15 11:06
HK-Listed GenFleet Jumps on Positive Progress of Cancer Drug
GenFleet-B Shares Rise Over 8% Intraday on Positive Progress in Multiple Domestic and Overseas Clinical Studies for GFH375/VS-7375
Deep News  ·  10-15 10:00
GenFleet-B Shares Rise Over 8% Intraday on Positive Progress in Multiple Domestic and Overseas Clinical Studies for GFH375/VS-7375
GenFleet Advances Oral KRAS G12D Inhibitor GFH375/VS-7375 to Multiple Phase III Trials after Robust Efficacy Signals in Pancreatic, Lung and Colorectal Cancers
Bulletin Express  ·  10-15 08:20
GenFleet Advances Oral KRAS G12D Inhibitor GFH375/VS-7375 to Multiple Phase III Trials after Robust Efficacy Signals in Pancreatic, Lung and Colorectal Cancers
GenFleet-B (02595): GFH375/VS-7375 Achieves Encouraging Progress in Multiple Domestic and Overseas Clinical Studies, Demonstrating Strong Efficacy Across Various RAS-Mutant Solid Tumors
Stock News  ·  10-15 08:04
GenFleet-B (02595): GFH375/VS-7375 Achieves Encouraging Progress in Multiple Domestic and Overseas Clinical Studies, Demonstrating Strong Efficacy Across Various RAS-Mutant Solid Tumors
Genfleet Therapeutics (Shanghai) - Gfh375 Receives Three Breakthrough Therapy Designations in China
THOMSON REUTERS  ·  10-15 08:00
Genfleet Therapeutics (Shanghai) - Gfh375 Receives Three Breakthrough Therapy Designations in China
GENFLEET-B Buys Back 38,000 H Shares, Raising Treasury Stock to 1.16 Million
Bulletin Express  ·  10-13
GENFLEET-B Buys Back 38,000 H Shares, Raising Treasury Stock to 1.16 Million
Movement Alert｜GENFLEET-B Falls 5.07% in Regular Trading, Shareholder Reduction and Limited Buyback Weigh on Sentiment
Market Focus  ·  10-13
Movement Alert｜GENFLEET-B Falls 5.07% in Regular Trading, Shareholder Reduction and Limited Buyback Weigh on Sentiment
Movement Alert｜GENFLEET-B Falls 5.11% in Regular Trading, Shareholder Reduction Pressure Coupled with Limited Buyback Support
Market Focus  ·  10-09
Movement Alert｜GENFLEET-B Falls 5.11% in Regular Trading, Shareholder Reduction Pressure Coupled with Limited Buyback Support
GENFLEET-B Executes HKD3.83 Million Share Buyback, Treasury Stock Climbs to 1.12 Million Shares
Bulletin Express  ·  10-08
GENFLEET-B Executes HKD3.83 Million Share Buyback, Treasury Stock Climbs to 1.12 Million Shares
GenFleet-B (02595) Spends HK$3.83 Million to Buy Back 135,000 Shares on October 8
Stock News  ·  10-08
GenFleet-B (02595) Spends HK$3.83 Million to Buy Back 135,000 Shares on October 8
Movement Alert｜GENFLEET-B Falls 6.61% in Regular Trading, Major Shareholder Reduction and Limited Buyback Trigger Selling Pressure
Market Focus  ·  10-08
Movement Alert｜GENFLEET-B Falls 6.61% in Regular Trading, Major Shareholder Reduction and Limited Buyback Trigger Selling Pressure
Movement Alert｜GENFLEET-B Falls 5.12% in Regular Trading, Shareholder Reduction and Limited Buyback Scale Trigger Selling Pressure
Market Focus  ·  10-07
Movement Alert｜GENFLEET-B Falls 5.12% in Regular Trading, Shareholder Reduction and Limited Buyback Scale Trigger Selling Pressure
GenFleet Therapeutics trims 0.28% of outstanding H-shares in September while maintaining required public float
Bulletin Express  ·  10-05
GenFleet Therapeutics trims 0.28% of outstanding H-shares in September while maintaining required public float
Movement Alert｜GENFLEET-B Falls 5.09% in Regular Trading, Profit-Taking After Rally as Major Shareholder Reduces Stake
Market Focus  ·  10-02
Movement Alert｜GENFLEET-B Falls 5.09% in Regular Trading, Profit-Taking After Rally as Major Shareholder Reduces Stake
HK Movers | Pharma Stocks Jump With CanSino Biologics up 19%, Joinn Laboratories up 17%
Tiger Newspress  ·  09-30
HK Movers | Pharma Stocks Jump With CanSino Biologics up 19%, Joinn Laboratories up 17%
Movement Alert｜GENFLEET-B Rises 5.27% in Regular Trading, GFH375 Breakthrough Therapy Designation and Ongoing Buybacks Boost Sentiment
Market Focus  ·  09-30
Movement Alert｜GENFLEET-B Rises 5.27% in Regular Trading, GFH375 Breakthrough Therapy Designation and Ongoing Buybacks Boost Sentiment
Ourea Biotech HK Limited Sells 6 Million Shares of GenFleet-B (02595) at HK$27.3 Each
Stock News  ·  09-29
Ourea Biotech HK Limited Sells 6 Million Shares of GenFleet-B (02595) at HK$27.3 Each

Introduction

Company Name.
GENFLEET-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
GenFleet Therapeutics (Shanghai) Inc is a China-based company principally engaged in the development of innovative drugs. The Company provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The Company is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The Company mainly primarily operates in the domestic and international markets.
Issue price:
--